tyrosine iodine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tyrosine iodine
• 英文别名: iodo (2S)-2-amino-3-(4-hydroxyphenyl)propanoate
• 化学式: C₉H₁₀INO₃
• 分子量: 307.088
• InChiKey: GVGLICCKAOWDRJ-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  glycine iodine 、 DL-酪氨酸 在 碘 、 溶剂黄146 作用下， 以 水 为溶剂， 生成 tyrosine iodine
  参考文献：
  名称：

  Aminoacid-iodine complex

  摘要：

  提供了一种氨基酸碘络合物，即氨基酸氨羧碘络合物，其中其配位中心是碘分子，复合试剂是氨基酸，复合反应的位点是氨基和氨基酸的羧基。该复合物可用于生产饲料、食品添加剂、消毒剂、防腐剂和药物。还提供了一种生产该复合物的方法，包括通过酸催化打开氨基酸的内环，并允许氨基酸与碘分子结合形成氨基酸氨羧碘复合物；由于氨基酸是一种营养物质，且氨羧复合物已达到，它们的引入不仅增加了复合物的营养功能并改善了碘的稳定性，而且有益于环境保护，增强了对病毒和细菌的消毒活性。

  公开号：

  US20030171598A1

文献信息

• Viral polymerase inhibitors
  申请人：——

  公开号：US20020065418A1

  公开（公告）日：2002-05-30

  A compound of the formula I: 1 wherein: X is CH or N; Y is O or S; Z is OH, NH 2 , NMeR 3 , NHR 3 ; OR 3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR 7 or CR 5 , wherein R 5 is H, halogen, or (C 1-6 ) alkyl and R 7 is H or (C 1-6 alkyl), with the proviso that X and A are not both N; R 6 is H, halogen, (C 1-6 alkyl) or OR 7 , wherein R 7 is H or (C 1-6 alkyl); R 1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C 1-3 )alkyl, (C 2-6 )alkenyl, phenyl(C 2-6 )alkenyl, (C 3-6 )cycloalkyl, (C 1-6 )alkyl, CF 3 , 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C 2-6 )alkenyl and phenyl(C 1-3 )alkyl), alkenyl, cycloalkyl, (C 1-6 )alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-3 )alkyl, (C 6-10 )bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R 3 is selected from H, (C 1-6 )alkyl, (C 3-6 )cycloalkyl, (C 3 6 )cycloalkyl(C 1-6 )alkyl, (C 6-10 )aryl, (C 6-10 )aryl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-6 )cycloalkyl(C 2-6 )alkenyl, (C 6-10 )aryl(C 2-6 )alkenyl, N{(C 1-6 )alkyl} 2 , NHCOO(C 1-6 )alkyl(C 6-10 )aryl, NHCO(C 6-10 )aryl, (C 1-6 )alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.

  该化合物的结构式为I:1，其中：X为CH或N；Y为O或S；Z为OH、NH2、NMeR3、NHR3、OR3或含有1至4个异原子（0、N和S）的5-或6-成员杂环，该杂环可选择性地与1至4个取代基取代；A为N、COR7或CR5，其中R5为H、卤素或（C1-6）烷基，R7为H或（C1-6）烷基，但X和A不能同时为N；R6为H、卤素、（C1-6）烷基或OR7，其中R7为H或（C1-6）烷基；R1选自包括含有1至4个异原子（O、N和S）的5-或6-成员杂环、苯基、苯基（C1-3）烷基、（C2-6）烯基、苯基（C2-6）烯基、（C3-6）环烷基、（C1-6）烷基、CF3、含有1至4个异原子（O、N和S）的9-或10-成员杂环的群体，其中该杂环、苯基、苯基（C2-6）烯基和苯基（C1-3）烷基、烯基、环烷基、（C1-6）烷基和杂环均可选择性地与1至4个取代基取代；R2选自（C1-6）烷基、（C3-7）环烷基、（C3-7）环烷基（C1-3）烷基、（C6-10）双环烷基、金刚烷基、苯基和吡啶基，所有这些基均可选择性地与1至4个取代基取代；R3选自H、（C1-6）烷基、（C3-6）环烷基、（C3-6）环烷基（C1-6）烷基、（C6-10）芳基、（C6-10）芳基（C1-6）烷基、（C2-6）烯基、（C3-6）环烷基（C2-6）烯基、（C6-10）芳基（C2-6）烯基、N(C1-6)烷基2、NHCOO(C1-6)烷基（C6-10）芳基、NHCO（C6-10）芳基、（C1-6）烷基-含有1至4个异原子（O、N和S）的5-或10-原子杂环和含有1至4个异原子（O、N和S）的5-或10-原子杂环；其中所述烷基、环烷基、芳基、烯基和杂环均可选择性地与1至4个取代基取代；n为零或1；或其可检测衍生物或盐。该发明的化合物可用作乙型肝炎病毒复制的抑制剂。该发明还提供了一种治疗或预防乙型肝炎病毒感染的方法。
• METHOD FOR PRODUCTION OF PROTEIN HAVING NON-NATURAL TYPE AMINO ACID INTEGRATED THEREIN
  申请人：Riken

  公开号：EP1961817A1

  公开（公告）日：2008-08-27

  This invention provides a method for producing proteins into which non-natural amino acids have been incorporated at desired positions involving the use of either prokaryote-derived or eukaryote-type aaRS* and prokaryotic cells or eukaryote-type as host cells, the method comprising steps of: (a) introducing genes encoding prokaryote-derived aminoacyl tRNA synthetase mutants having enhanced specificity to non-natural amino acids similar to given natural amino acids (compared with specificity to the natural amino acids) and tRNA genes for non-natural amino acids capable of binding to the non-natural amino acids in the presence of the prokaryote-derived aminoacyl tRNA synthetase mutants into prokaryotic cells that express genes encoding eukaryote-type aminoacyl tRNA synthetase having specificity to the given natural amino acids and tRNA genes capable of binding to the natural amino acids in the presence of eukaryote-type aminoacyl tRNA synthetase; and (b) knocking out genes encoding aminoacyl tRNA synthetase having specificity to the natural amino acids, which are inherent in the prokaryotic cells, and inherent tRNA genes capable of binding to the natural amino acids in the presence of the inherent aminoacyl tRNA synthetase.

  本发明提供了一种生产蛋白质的方法，该蛋白质在所需位置加入了非天然氨基酸，涉及使用原核生物或真核生物型 aaRS* 和原核细胞或真核生物型作为宿主细胞，该方法包括以下步骤：(a) 导入编码原核生物衍生的氨基酰 tRNA 合成酶突变体的基因，该突变体对类似于给定天然氨基酸的非天然氨基酸具有增强的特异性（与对天然氨基酸的特异性相比），以及编码在原核生物衍生的氨基酰 tRNA 合成酶存在时能够与非天然氨基酸结合的非天然氨基酸的 tRNA 基因(a) 在原核细胞中加入衍生的氨基酰 tRNA 合成酶突变体，这些突变体表达对特定天然氨基酸具有特异性的真核细胞型氨基酰 tRNA 合成酶编码基因，以及在真核细胞型氨基酰 tRNA 合成酶存在时能与天然氨基酸结合的 tRNA 基因；(b) 敲除原核细胞中固有的编码对天然氨基酸具有特异性的氨基酰 tRNA 合成酶的基因，以及在固有氨基酰 tRNA 合成酶存在时能与天然氨基酸结合的固有 tRNA 基因。
• ANTIBACTERIAL AGENT FOR TREATING INFECTIOUS DISEASES OF BACTERIAL ORIGIN
  申请人：Respublikanskoe Gosudarstvennoe Predpriyatie "Nauchnyj Centr Protivoinfekcionnyh Preparatov" Komiteta Promyshlennosti Ministerstva Industrii

  公开号：EP2722053A1

  公开（公告）日：2014-04-23

  The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [(Ln (MeI3) +) y [Me (Lm) I] + x} (Cl-) y + x + k] with M = 30-300 kDa.

  本发明涉及医学，即用于治疗包括医院感染和耐药结核病在内的传染性细菌疾病的抗菌剂，它是由碳水化合物蛋白质和/或多肽（白蛋白、白细胞介素、干扰素、信号蛋白等）合成的离子纳米结构复合物（INSC），通过激活至少含有一个末端氨基酸（如Phe、Ala、Val、Ala、Leu、Iu）的免疫细胞，增强体内的抗菌活性、等）合成的纳米结构复合物（INSC），通过激活至少含有一个末端氨基酸（如 Phe、Ala、Val、Ala、Leu、Ile 等）的免疫细胞，使其在一定的离子强度下，在第四阶段具有电子供体官能团、碘和碱及碱土元素的卤化物，从而增强体内的抗菌活性；增加抗菌剂：它还具有抗病毒活性，刺激骨髓造血功能；具有抗肿瘤作用和放射保护特性；在可接受的成分浓度下，可用作非药物制剂（BAFS 或准药物）；以药理学形式呈现，适合肠外、口服、外用或其他应用。INSC 的分子式为[(Ln (MeI3) +) y [Me (Lm) I] + x} (Cl-) y + x + k]，M = 30-300 kDa。
• Antibacterial agent for treating infectious diseases of bacterial origin
  申请人：Ilin Alexandr Ivanovich

  公开号：US10149890B2

  公开（公告）日：2018-12-11

  The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl−)y+x+k] with M=30-300 kDa.

  本发明涉及医学，即用于治疗包括医院感染和耐药结核病在内的传染性细菌疾病的抗菌剂，它是由碳水化合物蛋白质和/或多肽（白蛋白、白细胞介素、干扰素、信号蛋白等）合成的离子纳米结构复合物（INSC），通过激活至少含有一个末端氨基酸（如Phe、Ala、Val、Ala、Leu、Iu）的免疫细胞，增强体内的抗菌活性、等）合成的纳米结构复合物（INSC），通过激活至少含有一个末端氨基酸（如 Phe、Ala、Val、Ala、Leu、Ile 等）的免疫细胞，使其在一定的离子强度下，在第四阶段具有电子供体功能基团、碘和碱及碱土元素的卤化物，从而增强体内的抗菌活性；增加抗菌剂：它还具有抗病毒活性，刺激骨髓造血功能；具有抗肿瘤作用和放射保护特性；在可接受的成分浓度下，可用作非药物制剂（BAFS 或准药物）；以药理学形式呈现，适合肠外、口服、外用或其他应用。INSC 的分子式为[(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl-)y+x+k]，M=30-300 kDa。
• Compositions and methods for treatment and imaging using nanoparticles
  申请人：The Washington University

  公开号：US11007286B2

  公开（公告）日：2021-05-18

  The present invention encompasses compositions comprising two spectrally distinct radionuclides separated by a site susceptible to cleavage. Compositions of the invention may be used to detect enzyme activity and/or image diseases associated with said enzyme activity.

  本发明包括由两种光谱不同的放射性核素组成的组合物，这两种放射性核素被一个易裂解位点隔开。本发明的组合物可用于检测酶活性和/或成像与所述酶活性相关的疾病。